Effects of low and high dose oral contraceptives on blood coagulation and thrombogenesis induced by vascular subendothelium exposed to flowing human blood

Contraception

Volumn 43, Issue 5, 1991, Pages 435-446

  Inauen, Werner ^a   Stocker, Gabriela ^a   Haeberli, André ^a   Straub, P Werner ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL;

ADULT; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING; BLOOD FLOW VELOCITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT; VASCULAR ENDOTHELIUM;

BIOLOGY; BLOOD COAGULATION EFFECTS; CONTRACEPTION; CONTRACEPTIVE AGENTS, ESTROGEN--ANALYSIS; CONTRACEPTIVE AGENTS, FEMALE--ANALYSIS; CONTRACEPTIVE AGENTS--ANALYSIS; CONTRACEPTIVE METHODS--PHARMACODYNAMICS; CONTRACEPTIVE METHODS--SIDE EFFECTS; CONTRACEPTIVE USAGE; DEVELOPED COUNTRIES; DISEASES; EMBOLISM; ETHINYL ESTRADIOL--ANALYSIS; EUROPE; EXAMINATIONS AND DIAGNOSES; FAMILY PLANNING; HEMATOLOGICAL EFFECTS; HEMIC SYSTEM; LABORATORY EXAMINATIONS AND DIAGNOSES; METHOD ACCEPTABILITY; ORAL CONTRACEPTIVES, LOW-DOSE--PHARMACODYNAMICS; ORAL CONTRACEPTIVES, LOW-DOSE--SIDE EFFECTS; ORAL CONTRACEPTIVES--PHARMACODYNAMICS; ORAL CONTRACEPTIVES--SIDE EFFECTS; PHYSIOLOGY; RISK FACTORS; SWITZERLAND; THROMBOEMBOLISM; VASCULAR DISEASES; WESTERN EUROPE;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ANIMAL; ANTITHROMBIN III; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; BLOOD CELL COUNT; BLOOD COAGULATION; BLOOD PLATELETS; BLOOD VESSELS; CONTRACEPTIVES, ORAL, COMBINED; CREATININE; DESOGESTREL; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHINYL ESTRADIOL; FEMALE; FIBRIN; FIBRINOGEN; HEMATOCRIT; HEMOGLOBINS; HUMAN; NORPREGNENES; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; RABBITS; THROMBIN TIME;

EID: 0025876326     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/0010-7824(91)90134-2     Document Type: Article

References (45)

1. Investigation of deaths from pulmonary, coronary, and cerebral thrombosis and embolism in women of child-bearing age
2. Investigation of relation between use of oral contraceptives and thromboembolic disease
3. Investigation of relation between use of oral contraceptives and thromboembolic disease. A further report
4. Thromboembolism and oral contraceptives: An epidemiologic case-control study
5. Oral contraceptives and low antithrombin III activity
6. Effect of combined oestrogen-progestogen oral contraceptives, oestrogen and progestogen on antiplasmin and antithrombin activity
7. Association between oral contraceptive use and thromboembolism: A new approach to its investigation based on plasma fibrinogen chromatography
8. Oral contraceptives, antithrombin-III activity, and postoperative deep-vein thrombosis
9. AT III content and antithrombin activity in oestrogen-progestogen and progestogen-only treated women
10. Effect of oral contraceptives on antithrom-bin III
11. Decreased levels of histidine-rich glycoprotein (HRG) and increased levels of free plasminogen in women on oral contraceptives low in estrogen
12. Fibrinopeptide A plasma levels during low-estrogen oral contraceptive treatment
13. The effects of low-dose oral contraceptives on coagulation and fibrinolysis in two high-risk populations: Young female smokers and older premenopausal women
14. Increased euglobulin fibrinolytic potential in women on oral contraceptives low in oestrogen — Levels of extrinsic and intrinsic plasminogen activators, prekallikrein, factor XII, and C1-inactivator
15. The diurnal increase in euglobulin fibrinolytic activity in women using oral contraceptives and in normal women, and the generation of intrinsic fibrinolytic activity
16. Inhibition of tissue-type plasminogen activator in plasma of women using oral contraceptives and in normal women during a menstrual cycle
17. Oral contraceptives reduce total protein S but not free protein S
18. Effects of two low-dose oral contraceptives on circulating components of the coagulation and fibrinolytic system
19. Plasma and platelet lipid composition and platelet aggregation by arachidonic acid in women on the pill
20. Biosynthesis of platelet lipids in relation to aggregation in woman using oral contraceptives
21. Effect of oral contraceptives on plasma and platelet lipid composition
22. Vascular lesions in women taking oral contraceptives
23. Oral contraceptives and blood coagulation: A critical review
24. Effects of oral contraceptives on blood coagulation. A review
25. Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. I. Shear dependent decrease of adhesion in von Willebrand's disease and the Bernard-Soulier syndrome
26. Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. II. Relationship among platelet adhesion, thrombus dimensions and fibrin deposition
27. Role of shear rate and platelets in promoting fibrin formation on rabbit subendothelium.Studies utilizing patients with quantitative and qualitative defects
28. Platelet interaction with rabbit subendothelium in von Willebrand's disease: Altered thrombus formation distinct from defective platelet adhesion
29. Fibrin formation, fibrino-peptide A release, and platelet thrombus dimensions on subendothelium exposed to flowing native blood: Greater in factor XII and XI than in factor VIII and IX deficiency
30. Platelet adhesion and thrombus formation on subendothelium in platelets deficient in glycoproteins IIb–IIIa, Ib, and storage granules
31. Impaired interaction (adhesion-aggregation) of platelets with the subendothelium in storage-pool disease and after aspirin ingestion
32. Effect of aspirin and dipyridamole on the interaction of human platelets with subendothelium: studies using citrated and native blood
33. Dose-and shear rate-dependent effects of heparin on thrombogenesis induced by rabbit aorta subendothelium exposed to flowing human blood
34. Excessive deposition of fibrin, platelets and platelet thrombi on vascular subendothelium during contraceptive drug treatment
35. ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control
36. Platelet-surface interactions
37. Velocity profiles in annular perfusion chambers measured by laser-Doppler velocimetry
38. Aspirin inhibits platelet aggregation on, but not adhesion to, collagen fibrils: An assessment of platelet adhesion and deposited platelet mass by morphometry and Cr-labeling
39. Design and analysis
40. Oral contraceptives and thromboembolic disease Effects of lowering oestrogen content
41. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50 and 30 μg oestrogen preparations
42. Oral contraceptives and cardiovascular disease. First of two parts
43. Oral contraceptives and cardiovascular disease. Second of two parts
44. Plasma levels and pharmacokinetics of ethinyl estrogens in various populations. I. Ethinyl-estradiol
45. Variation of ethinylestradiol blood levels among healthy women using oral contraceptives